

# Complexity of Risks and Benefits

Tom A. Elasy, MD, MPH, Editor-in-Chief

Readers familiar with this journal have seen us cover a variety of clinical topics related to diabetes over the years. Although we have gone to significant efforts to stress the importance of diabetes care beyond glucose control, it is not surprising that a common theme of this journal has been the benefits of glucose control across settings and

populations. From the benefits of inpatient glucose control (p. 3) to pre-conception care of woman with type 2 diabetes, (p. 10), this theme is again highlighted in this issue.

Yet good clinicians understand that costs frequently accompany benefits of care. When speaking to a medical student who was simultaneously earning her Masters in

Business Administration degree, I likened the benefits of health care (with glucose control, those benefits include reductions in microvascular complications) to a “top-line” evaluation. It is essential, however, to have a “bottom-line” evaluation as well. Bottom-line evaluations would involve subtracting the costs (with glucose control, those costs may

## Clinical Diabetes

**Editor**  
Tom A. Elasy, MD, MPH

**Associate Editors**  
Michael J. Fowler, MD  
Martha M. Funnell, MS,  
RN, CDE  
Davida F. Kruger, MSN,  
APRN-BC, BC-ADM  
Michael Pignone, MD, MPH  
Russell L. Rothman, MD,  
MPP

**Editorial Board**  
Arti Bhan, MD  
Larry Deeb, MD  
Elizabeth Nardacci, MS,  
FNP-C, CDE, BC-ADM  
Patrick O'Connor, MD, MPH  
Heather Remtema, MPH,  
RD, CCRP  
Neil Skolnik, MD  
John White, PA, PharmD  
Carol Wysham, MD

**Director, Scholarly Journals**  
Christian S. Kohler

**Manager, Periodicals  
Production**  
Keang Hok

**Managing Editor**  
Debbie Kendall

**Associate Publisher**  
Howard Richman

**Advertising Production  
Specialist**  
Julie DeVoss

**Director, Membership/  
Subscription Services**  
James Skowrenski

**Associate Director,  
Billing & Collections**  
Laurie Ann Hall

### Advertising Representatives

*Pharmaceutical / Medical Accounts*  
B. Joseph Jackson, President; Paul Nalbandian, Vice  
President, Business Development; Charles Novak, Vice  
President, Sales; The Jackson Gaeta Group, Inc., 33 Smull  
Avenue, Caldwell, NJ 07006, (973) 403-7677



Audit Bureau  
of Circulations

Opinions expressed in signed articles are those of the authors and are not necessarily endorsed by the American Diabetes Association.

**American Diabetes  
Association Officers**

**Chair of the Board**  
John W. Griffin, Jr.

**President, Health Care  
& Education**  
Elizabeth Mayer-Davis,  
MSPH, PhD, RD

**President, Medicine & Science**  
Robert R. Henry, MD

**Secretary/Treasurer**  
Dwight Holing

**Chair of the Board-Elect**  
L. Hunter Limbaugh

**President-Elect, Health  
Care & Education**  
Geraldyn Spollett, MSN,  
ANP, CDE

**President-Elect,  
Medicine & Science**  
Vivian Fonseca, MD

**Secretary/Treasurer-Elect**  
Pearson C. Cummin, III

**Vice Chair of the Board**  
Karen D. Talmadge, PhD

**Vice President, Health  
Care & Education**  
Lurelean B. Gaines,  
RN, MSN

**Vice President, Medicine  
& Science**  
John E. Anderson, MD

**Vice Secretary/Treasurer**  
Patrick L. Shuler, CPA

**Chief Executive Officer**  
Larry Hausner, MBA

**Clinical  
Diabetes**<sup>TM</sup>

A PUBLICATION OF THE AMERICAN DIABETES ASSOCIATION®, INC.

### Clinical Diabetes Mission Statement

The mission of *Clinical Diabetes* is to provide primary care providers and all clinicians involved in the care of people with diabetes with information on advances and state-of-the-art care for people with diabetes. *Clinical Diabetes* is also a forum for discussing diabetes-related problems in practice, medical-legal issues, case studies, digests of recent research, and patient education materials.

### ADA Mission Statement

The mission of the American Diabetes Association is to prevent and cure diabetes and to improve the lives of all people affected by diabetes.

*Clinical Diabetes* (Print ISSN 0891-8929, Online ISSN 1945-4953) is published quarterly by the American Diabetes Association®, Inc., 1701 N. Beauregard St., Alexandria, VA 22311. Single issue rates are \$45 in the U.S., \$65 in Canada and Mexico (for Canada GST included), and \$75 in all other countries. Periodical postage paid at Alexandria, VA, and additional mailing offices. For subscription information, call toll free (800) 232-3472, 8:30 a.m. to 5:00 p.m. EST, Monday through Friday. Outside the U.S., call (703) 549-1500.

Claims for missing issues must be made within 6 months of publication. The publisher expects to supply missing issues free of charge only when losses have been sustained in transit and when the reserve stock permits.

Postmaster: Send change of address to *Clinical Diabetes* COA, 1701 N. Beauregard St., Alexandria, VA 22311-1717.

©American Diabetes Association®, Inc., 2011.  
Printed in the USA.

include hypoglycemia and weight gain) from the benefits to arrive at the net benefit, or cost, to patients. Even when we assign dollars values to human experiences, this is remarkably difficult.

In this issue of *Clinical Diabetes* (p. 36), Michael J. Fowler, MD, reviews hypoglycemia as part of our *Diabetes Foundation* series for physicians in training. Whether it is understanding the mechanisms underlying hypoglycemic events or prevention of future events, Fowler provides a nice synopsis for caregivers who are looking to better grasp this exceedingly undesirable consequence of glucose control.

Although more prevalent in individuals with type 1 diabetes who pursue rigorous glucose control, this consequence of diabetes control may be found across the spectrum of individuals with diabetes. Hypoglycemic events present as a spectrum of patient experiences that range from a simple jittery feeling to complete loss of consciousness with seizures. Rarely do I get a more visceral response from patients than when they describe a “bad low.” Most, if not all, *hate* the loss of control that can accompany such

events and the sense of being “off” for hours after one occurs.

In my practice, a desire to avoid hypoglycemia is a common reason my insulin-using patients fail to achieve glycemic targets that we had a priori decided were desirable. It is not surprising that many new pharmaceuticals for glycemic control no longer pursue an advantage in reducing glucose but a reduction in the frequency of hypoglycemia.

It can be challenging to get a handle on the bottom line when pursuing a strategy of ameliorating glucose control. Fortunately, many recent advances make the decision less gray than it may initially appear. The likelihood of hypoglycemia has been reduced with newer medications so that a more modern approach to glycemic control is likely to yield fewer events. Advances in our understanding of basic physiology have yielded a more prudent approach to preventing events, especially in the setting of a recent hypoglycemic event. A more structured assessment of patients’ recognition of hypoglycemia allows us to formulate different glycemic goals for those with diminished hypoglycemic awareness. Finally, proper education on the effects of

nutrition and physical activity are absolutely essential. Too often, we provide this information only in the context of how poor nutrition and inactivity lead to hyperglycemia, and we fail to provide the other side of the story, thinking that it will be intuitive. It is not.

When I was a young physician, a philosophy professor with a more than 20-year history of type 1 diabetes explained to me why he would not pursue a strategy of intensified glucose control. After explaining to me that parts of the Declaration of Independence were “lifted” from the English philosopher John Locke, he proceeded to provide a perspective on our “unalienable rights.” The famous “life, liberty, and the pursuit of happiness” were not equal to him. He could not, would not, tolerate the loss of liberty that hypoglycemia wrought. He would rather have the complications, or even loss of life, that can result from hyperglycemia. When I countered that blindness, dialysis, and amputations are also associated with loss of liberty, he wondered how I could value a distant outcome in a comparable manner to a present-day event.

We settled on an A1C in the mid-7s.